Medical device company Penumbra (NYSE:PEN) will be reporting results tomorrow after the bell. Here’s what investors should know.
Penumbra beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $315.5 million, up 10.8% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ EPS estimates.
Is Penumbra a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Penumbra’s revenue to grow 13.3% year on year to $315.7 million, slowing from the 15.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.67 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Penumbra has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average.
Looking at Penumbra’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Abbott Laboratories delivered year-on-year revenue growth of 4%, meeting analysts’ expectations, and Neogen reported a revenue decline of 3.4%, falling short of estimates by 1.5%. Abbott Laboratories traded up 3.8% following the results while Neogen was down 20%.
Read our full analysis of Abbott Laboratories’s results here and Neogen’s results here.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.